Do immune-related adverse events correlate with response to immune checkpoint inhibitors?

Immunotherapy. 2019 Mar;11(4):257-259. doi: 10.2217/imt-2018-0201.
No abstract available

Keywords: adverse events; atezolizumab; immune checkpoint inhibitors; immune-related; nivolumab; pembrolizumab.

Publication types

  • Editorial
  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Humans
  • Immune System Diseases / epidemiology*
  • Immunotherapy / adverse effects*
  • Immunotherapy / methods
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor